Clinical trials: Risperidone
Schizophrenia, Schizoaffective Disorder
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
Lyndra Therapeutics, Inc. is developing LYN-005, a long-acting oral (LAO) capsule (LYNX™ dosage form) of risperidone. This pivotal study (LYN-005-C-301) will evaluate the PK as well as safety and tolerability of multiple…
- Trial name
- NCT05779241
- Testing
- LYN-005, Risperidone
- Where
- 5 sites in United States
- Volunteers
- 83 people
- Sponsor
- Lyndra Inc.
Obsessive-Compulsive Disorder
Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)
This is a phase 2, randomized, controlled clinical trial to study the efficacy of pramipexol or risperidone in the treatment of refractory ODC patients.
- Trial name
- OCD-RT (NCT05401019)
- Testing
- Pramipexole, Risperidone
- Sponsor
- Clinical Academic Center (2CA-Braga)
Healthy
Risperidone 1 mg Tablets Dosed in Healthy Subjects Under Fed Conditions
The objective of this study was to compare the rate and extent of absorption of risperidone 1 mg tablets (test) versus Risperdal® (reference) administered as a 1 x 1 mg tablets under fed conditions.
- Trial name
- NCT00829894
- Testing
- Risperidone
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions
The objective of this study was to compare the rate and extent of absorption of risperidone 1 mg tablets (test) versus Risperdal® (reference) administered as a 1 x 1 mg tablet under fasting conditions.
- Trial name
- NCT00830349
- Testing
- Risperidone
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Apathy, Schizophrenia
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician …
- Conditions
- Apathy, Schizophrenia, Schizophrenia; Psychosis
- Trial name
- NCT06482554
- Testing
- Lumateperone 42 mg, Risperidone 2 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Schizophrenia
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
A clinical study to determine whether an investigational medication (SEP363856) changes how long it takes for food to move through the stomach into the small intestine in patients with schizophrenia.
- Trial name
- NCT05402111
- Testing
- SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia, and assess wether it affectsbody-weight associated parameters.
- Trial name
- NCT05542264
- Testing
- SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia Spectrum and Other Psychotic Disorders
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
Schizophrenia (SZ) is a highly debilitating neuropsychiatric disorder of young adulthood onset and a leading cause of disability worldwide.
- Trial name
- NCT03323437
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Psychosis, Intellectual Disability
Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
This clinical trial will prove whether a large number of people with intellectual disability and treatment-resistant psychosis could benefit from the use of clozapine.
- Trial name
- CLOZ-AID (NCT04529226)
- Testing
- Clozapine, haloperidol, pimozide, olanzapine, risperidone, amisulpride
- Where
- 20 sites in Spain
- Volunteers
- 75 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Bipolar Disorder
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
The objective of this retrospective observational study is to compare commonly prescribed bipolar disorder medications for their impact on: (1) hospitalization; (2) suicide attempts and self-harm; and (3) risk of drug-induced…
- Trial name
- NCT02893371
- Testing
- Lithium Carbonate, Lamotrigine, Valproic Acid
- Where
- United States
- Volunteers
- 1,037,352 people
- Sponsor
- University of New Mexico
Psychotic Disorders
Striatal Connectivity and Clinical Outcome in Psychosis
This is an observational neuroimaging treatment study. This study involves examining the neural circuitry of controlled treatment of patients presenting with a first-episode of psychosis with risperidone or aripiprazole.
- Trial name
- NCT02822092
- Testing
- Risperidone or Aripiprazole (patients only)
- Where
- United States
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Antipsychotics and Neuroleptics Toxicity
Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics
Atypical antipsychotic drugs are commonly used to treat psychiatric illnesses but they are significantly associated with side effects including acute dystonia, akathisia, parkinsonism (rigidity and tremor), tardive dyskinesia…
- Trial name
- NCT06200584
- Testing
- Risperidone, Olanzapine, Quetiapine
- Where
- Pakistan
- Volunteers
- 140 people
- Sponsor
- Dr Rabia Arshad
Autism Spectrum Disorder
Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
The aim of this study is to test whether therapeutic drug monitoring of risperidone in children with autism spectrum disorder and comorbid behavioral problems is able to reduce metabolic side effect burden, while retaining…
- Trial name
- SPACe2:STAR (NCT05146245)
- Testing
- Therapeutic Drug Monitoring, Risperidone plasma level
- Where
- Netherlands
- Volunteers
- 140 people
- Sponsor
- Erasmus Medical Center
Treatment-resistant Schizophrenia
The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset
Previous long-term follow-up studies on patients with first-episode schizophrenia have shown that up to 30% of patients who have never received antipsychotic medication treatment do not experience symptom relief or have poor…
- Trial name
- NCT06128408
- Testing
- risperidone, olanzapine, aripiprazole
- Volunteers
- 300 people
- Sponsor
- Peking University
Autism Spectrum Disorder
Electrical Brain Stimulation and Pharmacological Treatments in Autism Spectrum Disorder
This project aims to comparing the effectiveness of transcranial direct current stimulation with common pharmacological treatments on behavioral problems and cognitive deficits of children with autism spectrum disorder
- Trial name
- NCT05491720
- Testing
- RisperiDONE 1 MG/ML, transcranial direct current stimulation
- Where
- Iran
- Volunteers
- 45 people
- Sponsor
- The National Brain Mapping Laboratory (NBML)
Schizophrenia
Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia
This study design is subject to relevant SFDA regulations about clinical trials. Patients will be screened for inclusion into the study at the initial visit(240 patients to be recruited) and then undergo a minimum of 3-7 day's…
- Trial name
- NCT00202007
- Testing
- Aripiprazole tablet, 5-30mg/day, oral, 6 weeks, Risperidone tablet, 1-6mg/day, oral, 6 weeks
- Where
- 6 sites in China
- Volunteers
- 240 people
- Sponsor
- Otsuka Beijing Research Institute
Schizophrenia, Schizoaffective Disorder
Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths
This clinical trial is designed to evaluate different dosages of risperidone ISM, a new long-acting injectable form.
- Trial name
- PRISMA-1 (NCT01788774)
- Testing
- Risperidone ISM 50 mg, Risperidone ISM 75 mg, Risperidone ISM 100 mg
- Where
- 5 sites in Croatia, Russia and 2 more
- Volunteers
- 36 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia, Schizoaffective Disorder
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
- Trial name
- NCT04512066
- Testing
- RO6889450, Risperidone
- Where
- 40 sites in United States, Japan and 2 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
The Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level
EFFECT OF RISPERIDONE vs ARIPIPRAZOLE ON OXIDATIVE STRESS IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMIZED CONTROLLED TRIAL
The goal of this Randomized Controlled Trial is to to compare the effect of Risperidone vs Aripiprazole in terms of change in serum Glutathione level in patients with Autism Spectrum Disorder over a period of 6 weeks.
- Trial name
- versus (NCT05868720)
- Testing
- Risperidone, Aripiprazole
- Volunteers
- 42 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia
Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"
The aim of this study is observation, in an Italian real-world setting, of metabolic effects in patients with schizophrenia who will switch from any mono-therapy or poly-therapy antipsychotic regimen to monotherapy with…
- Trial name
- SWITCH (NCT04312503)
- Testing
- Lurasidone, aripiprazole, olanzapine, quetiapine or risperidone
- Where
- 18 sites in Italy
- Volunteers
- 95 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A